Datapoint: Keytruda Scores Major Kidney Cancer Nod

Keytruda’s latest FDA nod could give Merck a blockbuster edge in kidney cancer, as the PD-1 inhibitor on Nov. 18 became the first immunotherapy approved to treat early renal cell carcinoma at intermediate-high or high risk of recurrence. Renal cell carcinoma is the most common form of kidney cancer. Keytruda, in combination with Pfizer’s Inlyta, was initially approved as a first-line treatment for kidney cancer in August 2019. It holds covered or better status for 83% of all insured lives under the medical benefit, compared to 71% under the pharmacy benefit.

SOURCE: MMIT Analytics, as of 11/22/21

0 Comments

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
December 1

Datapoint: United to Join Massachusetts Duals Demo

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
November 30

Datapoint: Oscar, Emory to Offer New Health Plan in Georgia

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
November 23

Datapoint: Zing Health Acquires Lasso Healthcare

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today